Related Experiment Video
Updated: Mar 1, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Characterizing Risk Factors and Outcomes in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer Who Do
Giannis Mountzios1, Julius K Weng2, Eleni Zairi3
1Fourth Department of Medical Oncology and Clinical Trials Unit, Henry Dunant Hospital Center, Athens, Greece.
Introduction:
Many patients with unresectable stage III non-small-lung cancer (NSCLC) may face challenges in receiving consolidation durvalumab following concurrent chemoradiotherapy (cCRT) due to incomplete cCRT or disease progression. The retrospective POSITION study characterized this population.
Methods:
Adults with unresectable stage III NSCLC diagnosed between 2010 and 2021 who received cCRT were identified from TEMPUS Oncology (database). Among these patients, we estimated proportions with incomplete cCRT or progression during/within 42 days of cCRT and assessed overall survival (OS). Factors associated with incomplete cCRT or progression during/within 42 days of cCRT were identified via multivariable logistic regression.
Results:
Of 2076 eligible patients, 23.0% had incomplete cCRT (Group A), 12.7% experienced progression during/within 42 days of cCRT (Group B), and 64.3% completed cCRT without progression (Group C). Median OS (95% CI) was 21.6 (17.2-28.0), 10.1 (7.2-12.5), and 32.4 (29.8-34.6) months for Groups A, B, and C, respectively. Landmark 60-month OS rates were 26.3%, 11.6% and 33.2% for Groups A, B and C, respectively. Higher comorbidity burden (Charlson Comorbidity Index) and Black (vs. White) race were associated with higher likelihood of incomplete cCRT. Stage IIIB/C (vs. IIIA), cerebrovascular, and renal disease were associated with higher likelihood of progression during/within 42 days of cCRT.
Conclusion:
In POSITION, 35.7% of patients had incomplete cCRT or progressed during/within 42 days of cCRT and may have faced challenges receiving consolidation durvalumab; race, disease stage, and comorbidities were associated with incomplete cCRT or progression.
